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Background: The incidence of extended-spectrum beta-lactamase producing-enterobacteriacae (ESBL-E) infection
is rising worldwide. We aimed to determine the prevalence and nosocomial acquisition rate of ESBL-E as well as the
risk factors for ESBL-E carriage and acquisition amongst patients consecutively admitted to 13 internal medicine
units at our hospital who were not previously known to be ESBL-E carriers.
Findings: We screened all patients admitted or transferred to internal medicine units for ESBL-E on admission and
discharge using rectal swabs. Of 1072 patients screened, 51 (4.8%) were carriers of an ESBL-E at admission. Of 473 patients
who underwent admission and discharge screening, 21 (4.4%) acquired an ESBL-E. On multivariate analysis, diabetes
mellitus without end-organ complications (OR 2.87 [1.09-7.08]), connective tissue disease (OR 7.22 [1.17-44.59]), and liver
failure (OR 8.39 [1.55-45.45]) were independent risk factors for carriage of an ESBL-E upon admission to hospital (area
under the ROC curve, 0.68). Receipt of a first- or second-generation cephalosporin (OR 9.25 [2.22-37.82]), intra-hospital
transfer (OR 6.68 [1.71-26.06]), and a hospital stay >21 days (OR 25.17 [4.18-151.68]) were associated with acquisition of an
ESBL-E during hospitalisation; whilst admission from home was protective (OR 0.16 [0.06-0.39]) on univariate regression.
No risk profile with sufficient accuracy to predict previously unknown carriage on admission or acquisition of ESBL-E could
be developed using readily available patient information.
Conclusions: ESBL-E carriage is endemic amongst internal medicine patients at our institution. We were unable to
develop a clinical risk profile to accurately predict ESBL-E carriage amongst these patients.
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Introduction
ESBL-E are found worldwide with rates varying between
countries and institutions [1,2]. Infections with ESBL-E
are associated with increased morbidity and mortality
[3]. Early detection of ESBL-E carriage could allow
timely implementation of infection control measures
and the appropriate selection of antimicrobials [4]. On-
admission surveillance for ESBL-E has been associated
with a reduced incidence of ESBL-E infections during
hospitalisation [5]. However, universal screening for* Correspondence: stephan.harbarth@hcuge.ch
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reproduction in any medium, provided the orESBL-E is time consuming, expensive and unlikely to be
feasible [6,7]. Targeted screening based on clinical pre-
diction tools could therefore be useful. The development
of such tools requires knowledge of the local epidemi-
ology of ESBL-E [8].
We hypothesized that carriage of ESBL-E would be a
significant problem amongst internal medicine patients
at our institution and that readily available clinical data
could be used to formulate a prediction tool that could
accurately predict ESBL-E carriage upon admission to
our hospital.Setting and methods
The University of Geneva Hospital (HUG) is a 2200-bed
hospital providing in- and outpatient care for thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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population). From March to June 2010, all patients
>18 years of age consecutively admitted to 13 internal
medicine wards at HUG were screened for ESBL-E. Pa-
tients underwent admission and discharge rectal swabs
performed by ward nurses. Demographic data were col-
lected. Electronic patient records were reviewed retro-
spectively to obtain data on co-morbid conditions and
antibiotic use. This study was approved by the institu-
tional review board as a continuous quality improvement
project. No informed consent was therefore required.
Rectal swabs were plated directly onto chromID ESBL
medium (bioMérieux, Lyon, France). The presence of
ESBL-E was confirmed using the disc diffusion method
as described in the 2009 guidelines of the US Clinical
and Laboratory Standards Institute (www.clsi.org). This
study included ESBL- but not AmpC-producing Entero-
bacteriaceae, which were excluded by phenotypic con-
firmatory tests. A swab was defined as “on admission” if
it had been performed within 48 h of admission to an in-
ternal medicine unit. A “discharge swab” was performed
within 36 h of discharge. “In-hospital acquisition” was
established if patients had an ESBL-E identified on a dis-
charge swab where the admission swab had been nega-
tive. Laboratory records at HUG were used to identify
patients in whom an ESBL-E had been cultured previ-
ously. Patients who had a laboratory sample positive for
ESBL-E in the previous six months were identified as
previous ESBL-E carriers, and were excluded from the
risk factor analysis. This included both clinical isolates
and surveillance swabs. In addition, patients whose
swabs had not been performed within the pre-specified
time frames were excluded from the risk factor analysis.
Baseline characteristics of patients who were not cap-
tured by the screening programme were compared to
patients who were screened using chi squared tests for
categorical variables and student t tests for interval vari-
ables. Factors potentially associated with previously un-
known carriage of ESBL-E on admission and ESBL-E
acquisition on discharge were first evaluated using uni-
variate logistic regression. Variables were retained if the
P-value was <0.2. Multivariate models were then devel-
oped with stepwise elimination of variables using likeli-
hood ratio tests to compare each model to the previous
one. The performance of the final model was assessed
using the area under the receiver operating curve
(ROC), using STATA 11.2 (STATA Corp, College
Station, TX) for analysis.
Results
Of 1623 patients admitted to internal medicine, 1072
(66%) underwent admission screening within 48 hours
and 39 patients had admission screening performed out-
side of the 48-hour window. Patients who were notscreened at admission were slightly younger (median
age, 59.5 vs 62.3 years; p = 0.006), more likely to be
transferred to internal medicine from another unit ra-
ther than directly admitted (4.2% vs 2.4%; p = 0.023) and
were less likely to suffer from acute renal failure (16.7%
vs 23.0%; p = 0.028).
Overall, 487 (30%) underwent discharge screening. Pa-
tients who failed to have discharge screening performed
were younger (median age, 63.1 years vs 66.7 years;
p = 0.001) and less likely to have chronic obstructive pul-
monary disease (11.2% vs 20.2%; p = 0.001) and carotid
artery stenosis (0.5% vs 2.2%; p = 0.027) than those who
did undergo discharge screening. There were more
males in the group who missed discharge screening
(male sex, 60.2% vs 52.1%; p = 0.002).
Of 1072 patients who had appropriate admission
screening performed, median age was 62.3 years (95%
confidence interval, 61.1-63.4) and 56.4% (n = 627) were
male. The majority of patients (91.0% [89.2-92.6%]) were
admitted to internal medicine directly, whilst 72 (6.7%
[5.2-8.1%]) were transferred from the intensive care unit
and 26 (2.4% [1.5-3.3%]) were transferred from another
hospital unit. Among the 225 patients for whom previ-
ous laboratory data were available, 28 (16.0% [11.1-
20.8%]) had a laboratory sample that was previously
positive for ESBL-E, and were identified as previous
ESBL-E carriers. Of 1072 patients screened at admission,
4.8% (51/1072) were identified as ESBL-E carriers. Of
487 patients screened at discharge, 14 were identified as
previous ESBL-E carriers and were excluded from the
analysis. Of the remaining 473 patients without previ-
ously known ESBL-E carriage, 4.4% (21/473) acquired an
ESBL-E during their hospital admission (without clinic-
ally symptomatic infection). The most commonly identi-
fied enterobacteriaceae on screening (admission and
discharge swabs combined) were Escherichia coli (75.6%
[65.9-85.3%]), followed by Enterobacter cloacae (5.2% [0.1-
10.1]), Citrobacter freundii (5.1% [0.1-10.1]), Morganella
morganii (3.8% [−0.5-8.2]), and Proteus mirabilis (2.6%
[−1.0-6.2]). Other enterobacteraciae, including Klebsiella
pneumoniae accounted for 1% or less of isolates.
The results of multivariate logistic regression examining
factors potentially associated with previously unknown
carriage of ESBL-E on admission/transfer to internal
medicine are presented in Table 1. Diabetes mellitus with-
out end-organ complications, connective tissue disease,
and liver failure were identified as independent risk factors
for ESBL-E carriage upon admission. However, this multi-
variate model had low predictive accuracy (area under the
ROC curve, 0.68).
On univariate regression transfer to internal medicine
from another unit and from the intensive care unit were
risk factors for nosocomial acquisition of an ESBL-E,
whilst admission from home was protective (all P-values
Table 1 Factors associated with ESBL-E carriage amongst 1072 internal medicine patients, University of Geneva
Hospitals, March-June 20101; univariate and multivariate regression analysis





OR [95% CI] P-value OR [95% CI] P-value
Male gender 54.9 (28) 56.9 (581) 0.92 [0.52-1.62] 0.778
Transferred from ICU 0 0.6 (6) 0.27 [0.36-1.97] 0.195
Transferred from other ward (other than the ICU) 2.0 (1) 2.5 (25) 0.80 [0.11-6.00] 0.825
Patient admitted from home 96.1 (49) 90.7 (925) 2.52 [0.61-10.62] 0.201
Age
< =59 y 37.3 (19) 33.6 (343) 1.94 [0.55-6.81] 0.300
60 -79 y 41.2 (21) 39.5 (403) 1.62 [0.47-5.52] 0.443
> = 80 y 21.5 (11) 22.1 (226) 1.40 [0.38-5.2] 0.614
Acute renal failure2 20.8 (5) 23.0 (94) 0.87 [0.32-2.40] 0.793
Chronic renal failure2 16.7 (4) 13.6 (55) 1.28 [0.42-3.87] 0.667
End stage renal failure2 4.2 (9) 2.0 (8) 2.16 [0.26-18.04] 0.476
Diabetes without complications2 33.3 (8) 15.3 (62) 2.77 [1.14-6.39] 0.033 2.87 [1.09-7.08] 0.032
Diabetes mellitus (with complications)2 12.5 (3) 10.3 (42) 1.24 [0.35- 4.33] 0.706
Peripheral vascular disease2 8.3 (16) 3.9 (16) 2.21 [0.48-10.25] 0.309
Chronic obstructive airway disease2 20.8 (5) 13.8 (56) 1.64 [0.59-4.58] 0.341
Dementia2 0 1.2 (5) Omitted
Stroke2 0 1.0 (4) Omitted
Cerebral hemorrhage2 0 0.5 (2) Omitted
Congestive cardiac failure2 29.2 (7) 23.7 (96) 1.33 [0.54-3.30] 0.539
Ischemic heart disease2 12.5 (3) 11.1 (45) 1.15 [0.33-4.00] 0.831
Hematological malignancy2 0 5.4 (22) Omitted
Carotid artery stenosis2 0 1.0 (4) Omitted
Parkinson’s disease2 0 0.3 (1) Omitted
Connective tissue disease2 8.3 (5) 1.0 (4) 9.14 [1.58-52.62] 0.013 7.22 [1.17-44.59] 0.033
Liver failure2 8.3 (6) 1.5 (6) 6.06 [1.15-31.77] 0.033 8.39 [1.55-45.45] 0.014
Respiratory failure2 0 0.7 (3) Omitted
Solid organ cancer2 4.2 (1) 17.0 (69) 0.21 [0.28-1.58] 0.130
Metastatic cancer2 8.3 (2) 8.4 (34) 0.99 [0.22-4.41] 0.994
Peptic ulcer disease2 4.2 (1) 2.7 (11) 1.56 [0.19-12.64] 0.676
Infection2 0 0.9 (4) Omitted
1. Positive ESBL swab at admission in cases where the swab was collected within 48 h of admission and patients with prior carriage have been excluded.
ICU intensive care unit, y years;
2. Denominator adjusted for number of patients in whom data were available.
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tion were: hospital stay >21 days and receipt of a first- or
second- generation cephalosporin. These data are pre-
sented in detail in Table 2. We did not perform multivari-
ate regression modeling to predict nosocomial acquisition
of ESBL-E, due to the small number of patients who ac-
quired ESBL-E.
Discussion
Our prevalence of on-admission ESBL-E carriage of 4.8%
is similar to other European studies where rates rangingfrom 2.7 to 30% have been observed [9]. There are no
published population-based studies of ESBL-E carriage
rates from Switzerland, but the 2010 Swiss national sur-
veillance program (www.antibioticresistance.ch) found
that amongst hospitalized patients, 5.8% of E. coli and
7.1% of K. pneumoniae were resistant to third-generation
cephalosporins. On-admission carriage rates of 16-27% for
ESBL-E have been previously described at our institution
when “high risk” groups (patients migrating from, or pre-
viously hospitalized in a country with a high prevalence of
ESBL-E) were targeted [10].
Table 2 Factors associated with ESBL-E acquisition amongst 473 internal medicine patients, University of Geneva
Hospitals, March-June 20101; univariate regression analysis
Proportions (n) or Median [range] Univariate regression
Variable ESBL acquisition (n = 21) No ESBL acquisition (n = 452) OR [95% CI] P-value
Male gender 57.1 (12) 51.3 (232) 1.2 [0.51-3.05] 0.603
Transferred from ICU 28.6 (6) 8.2 (37) 4.48 [1.64-12.25 0.003
Transferred from other ward (other than the ICU) 14.3 (3) 2.4 (11) 6.69 [1.71-26.06] 0.006
Patient admitted from home 57.1 (12) 89.4 (404) 0.16 [0.06-0.39] <0.001
Age (y) 66.9 [30.6-86.8] 64.1 [18.8-99.2]
Age
< = 59 y 1.45 [0.16-12.90] 0.737
60 -79 y 1.35 [0.16-11.19] 0.778
> = 80 y 1.89 [0.23-15.99] 0.556
Length of stay (days) 12.1 [3–58] 7.7 [1–54]
Length of stay
<7 d 2.69 [0.73-9.95] 0.138
7-14 d 3.09 [0.67-14.23] 0.146
14-21 d 1.5 [0.15-15.13] 0.718
>21 d 25.17 [4.18-151.7] <0.001
Acute renal failure2 45.4 (5) 22.7 (45) 2.83 [0.83-9.71] 0.098
Chronic renal failure2 27.2 (3) 14.6 (29) 2.12 [0.55-8.72] 0.268
End stage renal failure2 0.0 (0) 3.0 (6) Omitted
Diabetes without complications2 9.1 (1) 18.4 (38) 0.45 [0.05-3.62] 0.453
Diabetes mellitus (with complications)2 9.1 (1) 11.6 (23) 0.76 [0.09-6.22] 0.799
Peripheral vascular disease2 0.0 (0) 5.1 (11) Omitted
Chronic obstructive airway disease2 18.2 (2) 21.2 (42) 0.83 [0.17-3.96] 0.811
Dementia2 0.0 (0) 1.0 (2) Omitted
Stroke2 0.0 (0) 1.0 (2) Omitted
Cerebral hemorrhage2 0.0 (0) 1.0 (2) Omitted
Congestive cardiac failure2 9.1 (1) 25.8 (51) 0.29 [0.04-2.30] 0.241
Ischemic heart disease2 0.0 (0) 9.6 (19) Omitted
Hematological malignancy2 0.0 (0) 5.1 (11) Omitted
Carotid artery stenosis2 0.0 (0) 2.5 (5) Omitted
Parkinson’s disease2 9.1 (1) 0.5 (1) 19.70 [1.15-338.43] 0.040
Connective tissue disease2 0.0 (0) 1.0 (2) Omitted
Liver failure2 9.1 (1) 1.0 (2) 9.80 [0.82-117.39] 0.072
Respiratory failure2 0.0 (0) 0.5 (1) Omitted
Solid organ cancer2 18.1 (2) 14.1 (28) 1.35 [0.27-6.57] 0.711
Metastatic cancer2 0.0 (0) 6.6 (13) Omitted
Peptic ulcer disease2 9.1 (1) 3.0 (6) 3.20 [0.35-29.18] 0.302
Infection2 0.0 (0) 0.5 (1) Omitted
Any antibiotic use 42.9 (9) 26.5 (120) 2.08 [0.85-5.04] 0.108
Amoxicillin, flucloxacillin, phenoxymethylpenicillin 14.3 (3) 8.6 (39) 1.76 [0.49-6.25] 0.379
Ceftriaxon 4.8 (1) 1.3 (6) 3.72 [0.43-32.35] 0.234
Cefazolin, cefuroxime 14.3 (3) 1.8 (8) 9.25 [2.22-37.82] 0.002
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Table 2 Factors associated with ESBL-E acquisition amongst 473 internal medicine patients, University of Geneva
Hospitals, March-June 20101; univariate regression analysis (Continued)
Macrolide, tetracycline 0.0 (0) 1.3 (6) Omitted
Fluoroquinolone 0.0 (0) 6.0 (27) Omitted
Ertapenem, imipenem, meropenem 0.0 (0) 0.2 (1) Omitted
Cotrimoxazole 0.0 (0) 1.3 (6) Omitted
Vancomycin 4.8 (1) 0.4 (2) 11.34 [0.97-129.31] 0.052
Metronidazole 4.8 (1) 1.8 (8) 2.84 [0.33-23.27] 0.347
Gentamicin 0.0 (0) 0.3 (1) Omitted
1. Positive ESBL swab at discharge where admission ESBL-E screening had been negative. Swabs must be collected within 36 h of discharge and patients with
prior ESBL-E carriage were excluded.
ICU intensive care unit; y years, d days;
2. Denominator adjusted for number of patients in whom data were available.
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ducing K. pneumoniae found in this study. This finding
is surprising, given this organism comprised 32% of the
ESBL-E found in previous studies at our institution [10].
A possible explanation could be that previously reported
higher rates of ESBL-Klebsiella spp were documented in
patients transferred from abroad, whereas the current
study focused more on community carriers of ESBL-E
that could be related to the food reservoir of resistant
E.coli.
The largest study to examine risk factors for carriage
of ESBL-E on admission to hospital is a meta-analysis
by Ben-Ami et al., which included 3 studies of on-
admission ESBL-E carriage from hospitals in Tel-Aviv
and Spain [11]. Male gender, age > 65 years, admission
from a long-term care facility, and recent antibiotic use
were independent risk factors for ESBL-E on-admission
carriage. Despite the fact that the authors had a com-
bined dataset of over 900 ESBL-E-positive patients, the
multivariate model was still poorly predictive of ESBL-E
carriage. We found that a past history of liver disease,
diabetes mellitus, and connective tissue disease were as-
sociated with carriage of ESBL-E upon admission. Whilst
liver disease has been identified as a risk factor for
on-admission ESBL carriage elsewhere [12], diabetes
mellitus and connective tissue disease have not. Infections
with ESBL-E in patients with severe liver disease are asso-
ciated with poorer outcomes [13,14]. The mechanisms
underlying this association require further elucidation.
One possibility is that chronic liver disease may be acting
as a surrogate marker for prophylactic fluoroquinolone
use against spontaneous bacterial peritonitis — a known
risk factor for ESBL-E acquisition [15,16].
Our model was poorly predictive of ESBL-E carriage
upon admission to our hospital and this has been found
by other studies [11]. Indeed, Ben-Ami et al. found that
20% of patients colonized with ESBL-E at admission had
no identifiable risk factors [17]. Similarly, Ruppe et al.
studied on-admission characteristics of 500 internalmedicine patients and were unable to develop a tool that
could effectively predict ESBL-E carriage on admission
to their hospital [18].
Few studies have examined the risk factors for acquir-
ing colonization with ESBL-E during hospitalization.
Buke et al. found that the presence of a rapidly or ultim-
ately fatal disease on admission (as measured by a high
McCabe score) was associated with ESBL-E colonization
on day 30 of admission [19]. Duration of urinary cathe-
terization and mechanical ventilation were found to
be risk factors for colonization with ESBL-producing
K. pneumoniae in a Spanish intensive care unit [20]. We
found that a prolonged hospital stay and cephalosporin
use were associated with acquisition of ESBL-E carriage.
These factors have previously been found to be associ-
ated with nosocomial infection with ESBL-E [12,21-23].
Our study has several limitations. First, a large propor-
tion of patients failed to have screening performed. Pa-
tients who did not have admission screening performed
were younger, more likely to be transferred to internal
medicine rather than directly admitted, and less likely to
have acute renal failure. The increased proportion of
transferred rather than directly admitted patients in
those who missed admission screening probably reflects
that these patients were not perceived as ‘new’ patients
by nursing staff making it more likely that screening
would be forgotten. It is unclear why there was a smaller
proportion of patients with acute renal failure in those
who missed screening. As younger patients tend to be
less likely to be ESBL-E carriers the failure to capture
these patients may have caused the prevalence of ESBL-
E carriage in our patients to be overestimated. Patients
who failed to have discharge screening performed were
younger and more frequently male than patients who
did undergo discharge screening. A possible explanation
for these differences might be that younger men were
more reluctant to undergo rectal swabs. Nursing staff
may also have had less opportunity to capture these pa-
tients for screening at the point of discharge. The
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estimate of our ESBL-E acquisition rate given that youn-
ger healthier patients would be less likely to have ac-
quired an ESBL-E during their hospital stay. Second, we
used rectal surveillance cultures to detect ESBL-E and
these have several well-described limitations [24] with a
sensitivity ranging from 42-78% [25,26]. We defined
ESBL-E acquisition as the detection of ESBL-E on dis-
charge rectal screening where the admission swab had
been negative; however, we cannot exclude the possibil-
ity that some patients may have had a “falsely negative”
admission swab which could occur because of poor col-
lection technique, initial carriage in urine with later
transmission to the gastrointestinal tract or low level of
colonization at admission with increased bacterial dens-
ity following antibiotic exposure during hospitalisation
[25]. Third, this study was conducted amongst internal
medicine patients at a single institution and thus our
findings might not be generalizable to other settings and
patient populations.
Nevertheless, our study provides valuable information
on the prevalence and epidemiology of ESBL-E at this
Swiss tertiary care hospital. Our failure to identify a pre-
dictive risk profile of previously unknown ESBL-E when
using readily available clinical data highlights the diffi-
culties in implementing targeted ESBL-E on-admission
screening programs.
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